🔥🐔 BizChicken 🐔🔥
Companies Similar to Tango Therapeutics, Inc.
Sign Up Today!
Sign up for BizChicken and discover more about the corporations around you.
CARGO Therapeutics, Inc. Common Stock
CRG-022
CARGO Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing chimeric antigen receptor (CAR) T-cell therapies for cancer patients. Their lead program, CRG-022, targets resistance mechanisms in B-cell malignancies.
About | Leadership | Directors | About | Contact | Contact | Careers | Careers | Careers | Careers | About | About
Symbol: CRGX
Recent Price: $13.76
Industry: Biotechnology
CEO: Ms. Gina Chapman
Sector: Healthcare
Employees: 150
Address: 1900 Alameda De Las Pulgas, San Mateo, null 94403
Phone: 650-379-6143
Leadership
- Gina Chapman, President and Chief Executive Officer
- Anup Radhakrishnan, Chief Financial Officer/Chief Business Officer
- Ginna Laport, MD, Chief Medical Officer
- Shishir Gadam, PhD, Chief Technical Officer
- Michael Ports, PhD, Chief Scientific Officer
- Kari Leetch, Chief People Officer
- Halley Gilbert, JD, Chief Legal Officer
- Bethany Rogers, SVP, Product Strategy and Commercialization
- Faisal Shawwa, SVP, Finance
- Tonia J. Buchholz, PhD, Head of Clinical Science
- Kanika Chawla, PhD, Head of Process Sciences
- Sandra Chen, Head of Clinical Quality and Risk Management
- Michelle Gray, Head of Clinical Operations
- Adam Haskett, Head of External Manufacturing
- David Hoffman, JD, Head of Intellectual Property & Transactions
- Anissa Irwin, Head of Quality Assurance and Systems
- Brett Masterson, Head of Marketing
- Rob McCombie, Head of CMC Regulatory
- Frank McDonald, Head of Clinical Data Management
- Priya Parameswaran, Head of Corporate Strategy and Business Operations
- Shabnum Patel, PHD, Head of MSAT
- Mary Rodley, Head of CMC Strategy and Operations
- Abhijeet Sarvaiya, Head of Statistical Programming
- Brian Schoelkopf, Head of FP&A
- Christophe Suchet, Head of IT
- Beth Vasievich, PhD, Head of Commercial Planning and Operations
- Jun Wang, Head of Procurement
- John Orwin, Chairman of the Board
- Abraham Bassan, Board Director
- Kapil Dhingra, M.B.B.S, Board Director
- Reid Huber, PHD, Board Director
- David Lubner, Board Director
- Krishnan Viswanadhan, Pharm.D, Board Director
- Jane Pritchett Henderson, Board Director
Last updated: 2024-12-31
Candel Therapeutics, Inc.
CAN-2409, CAN-3110
Candel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing immunotherapies for cancer patients, with products like CAN-2409 and CAN-3110 in various clinical trial phases.
About | About | About | About | Contact | Careers | Careers | About | About | About | Careers | About
Symbol: CADL
Recent Price: $7.95
Industry: Biotechnology
CEO: Dr. Paul-Peter Tak FOCIS, M.D., Ph.D.
Sector: Healthcare
Employees: 42
Address: 117 Kendrick Street, Needham, MA 02494
Phone: 617 916 5445
Last updated: 2024-12-31
Sangamo Therapeutics, Inc.
ZFP Technology Platform
Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company that develops genomic medicines using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation with a focus on transforming patients' lives.
Contact | About | About | Leadership | Leadership | About | About | About | About | About | About | About | About | About | About | Careers | Vision/Values | DEI | Benefits | About | About | About | About | About | About | About | News | Events | Vision/Values | DEI | Benefits | Careers | Careers | About | About
Symbol: SGMO
Recent Price: $2.34
Industry: Biotechnology
CEO: Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D.
Sector: Healthcare
Employees: 405
Address: 501 Canal Blvd, Brisbane California, CALIFORNIA 94005
Phone: 510 970 6000
Leadership
- Sandy Macrae, M.B., Ch.B., Ph.D.,
- Gregory Davis, Ph.D., Head of Research and Technology
- Nathalie Dubois-Stringfellow, Ph.D., Chief Development Officer
- Prathyusha Duraibabu, Chief Financial Officer
- Phillip Ramsey, Head of Technical Operations
- Stephanie J. Seiler, CLP, Head of Business Development & Alliance Management
- Louise Wilkie, Global Corporate Communications and Investor Relations
- Scott Willoughby, General Counsel and Corporate Secretary
- H. Stewart Parker, Chair of the Board
- Courtney Beers, Ph.D.,
- Robert Carey,
- Kenneth Hillan, M.B. Ch.B.,
- Margaret (Peg) A. Horn, J.D.,
- John Markels, Ph.D.,
- James R. Meyers,
- Karen Smith, M.D., Ph.D., M.B.A., LLM,
Last updated: 2024-12-31
Tenaya Therapeutics, Inc.
TN-201, TN-301, TN-401
Tenaya Therapeutics, Inc. is a biotechnology company that discovers, develops, and delivers therapies for heart disease using cellular regeneration, gene therapy, and precision medicine platforms.
Symbol: TNYA
Recent Price: $1.45
Industry: Biotechnology
CEO: Mr. Faraz Ali M.B.A.
Sector: Healthcare
Employees: 140
Address: 171 Oyster Point Boulevard, South San Francisco, CA 94080
Phone: 650 825 6900
Last updated: 2024-12-31
Taysha Gene Therapies, Inc.
TSHA-120, TSHA-102, TSHA-121, TSHA-118, TSHA-105, TSHA-101
Taysha Gene Therapies, Inc. focuses on developing adeno-associated virus-based gene therapies for treating monogenic diseases of the central nervous system, with a pipeline including treatments for conditions such as giant axonal neuropathy, Rett syndrome, and GM2 gangliosidosis.
Symbol: TSHA
Recent Price: $1.73
Industry: Biotechnology
CEO: Mr. Sean P. Nolan
Sector: Healthcare
Employees: 52
Address: 3000 Pegasus Park Drive, Dallas, TX 75247
Phone: 214 612 0000
Last updated: 2024-12-31
Atara Biotherapeutics, Inc.
T-cell immunotherapy treatments
Atara Biotherapeutics, Inc. is a company focused on developing off-the-shelf T-cell immunotherapy treatments for patients with cancer, autoimmune, and viral diseases, including tabelecleucel for EBV driven diseases, next-generation CAR T therapies, and the ATA368 program for HPV associated cancers.
About | About | About | Contact | About | Careers | Careers | About | Careers | Careers | About | About
Symbol: ATRA
Recent Price: $13.28
Industry: Biotechnology
CEO: Dr. Anhco Nguyen Ph.D.
Sector: Healthcare
Employees: 165
Address: 611 Gateway Boulevard, South San Francisco, CA 94080
Phone: 650 278 8930
Last updated: 2024-12-31
Black Diamond Therapeutics, Inc.
BDTX-189, BDTX-1535, BDTX-4933
Black Diamond Therapeutics, Inc. is a biotechnology company that discovers, develops, and commercializes medicines for patients with genetically defined tumors. The company focuses on creating irreversible small molecule inhibitors to target specific oncogenic proteins.
Symbol: BDTX
Recent Price: $2.15
Industry: Biotechnology
CEO: Dr. Mark A. Velleca M.D., Ph.D.
Sector: Healthcare
Employees: 54
Address: One Main Street, Cambridge, MA 02142
Phone: 617 252 0848
Leadership
- Ali Behbahani, M.D., Co-Head of Healthcare, NEA
- Shannon Campbell, Executive Vice President and Chief Commercial Officer, Merus
- Kapil Dhingra, M.D., Former Head, Roche Oncology Development
- Samarth (Sam) Kulkarni, Ph.D., CEO, CRISPR Therapeutics AG
- Garry E. Menzel, Ph.D., Operating Partner, GHO Capital Partners LLP
- Prakash Raman, Ph.D., CEO of InduPro, Inc.
- Mark A. Velleca, M.D., Ph.D., CEO and Board Chair
Last updated: 2024-12-31
Cogent Biosciences, Inc.
CGT9486
Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases, with lead product candidate CGT9486 targeting mutations driving systemic mastocytosis and advanced gastrointestinal stromal tumors.
Symbol: COGT
Recent Price: $7.67
Industry: Biotechnology
CEO: Mr. Andrew R. Robbins M.B.A.
Sector: Healthcare
Employees: 164
Address: 200 Cambridge Park Drive, Cambridge, MA 02140
Phone: 617 945 5576
Last updated: 2024-12-31
Inhibikase Therapeutics, Inc.
Ik T-148009
Inhibikase Therapeutics, Inc. is a clinical stage pharmaceutical company focused on developing therapeutics for Parkinson's Disease and related disorders. Their product pipeline includes treatments for neurological and cancer-related conditions.
About | Leadership | Directors | About | About | About | Contact | Careers | About | About | About | About
Symbol: IKT
Recent Price: $3.24
Industry: Biotechnology
CEO: Dr. Milton H. Werner Ph.D.
Sector: Healthcare
Employees: 8
Address: 3350 Riverwood Parkway SE, Atlanta, GA 30339
Phone: 678 392 3419
Leadership
- Milton H. Werner, Ph.D., President and CEO
- C. Warren Olanow MD, FRCPC, FRCP (Hon.), Medical Consultant and CEO of Clintrex Research Corporation
- Garth Lees-Rolfe, CPA, Chief Financial Officer
- Dan Williams, Controller
- Terence Kelly, Ph.D., Medicinal Chemistry Consultant
- Surendra Singh, Ph.D., Chemistry and Manufacturing Controls
- Merrill M. Kraines, Partner, McDermott, Will & Emery, Outside General Counsel
- Roberto Bellini, Managing Partner at BSQUARED Capital
- Dennis Berman, Serial Entrepreneur
- David Canner, Ph.D., Partner at Soleus Capital
- Roy Freeman, M.D., Professor of Neurology at the Harvard Medical School, Director of the Center for Autonomic and Peripheral Nerve Disorders, Beth Israel Deaconess Medical Center
- Arvind Kush, Chief Financial Officer and Chief Business Officer of Candid Therapeutics
- Amit Munshi, Chief Executive Officer of Orna Therapeutics
Last updated: 2024-12-31
Intensity Therapeutics, Inc.
INT230-6
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of cancer drugs for treating solid tumors. Their lead product, INT230-6, is undergoing Phase 2 trials for various cancers and is being tested in collaborations with major pharmaceutical companies.
Symbol: INTS
Recent Price: $1.82
Industry: Biotechnology
CEO: Mr. Lewis H. Bender M.A., M.B.A., M.S.
Sector: Healthcare
Employees: 5
Address: 61 Wilton Road, Westport, CT 06880
Phone: 203 221 7381
Leadership
- Lewis H. Bender, M.S., M.A., M.B.A., Founder and CEO
- Joseph Talamo, CPA, Chief Financial Officer
- James M. Ahlers, Executive Vice President
- Brian Schwartz, MD, Executive VP, Clinical Development
- John Wesolowski, CPA, MBA, Principal Accounting Officer and Controller
- Kimberly A. Guedes, RN, MBA, Vice President of Clinical Operations
- Doranne Frano, Regulatory Affairs and Quality Control
- Daniel J. Donovan, Board Member and Chief Executive Officer
- Tom Dubin, Board Member
- Mark A. Goldberg, MD, Board Member
- Emer Leahy, Ph.D., Board Member
Last updated: 2024-12-31
Nurix Therapeutics, Inc.
NX-2127, NX-5948, NX-1607, NX-0255
Nurix Therapeutics, Inc. is a biopharmaceutical company that focuses on developing small molecule therapies for cancer and immune disorders, with products targeting BTK and CBL-B proteins. The company collaborates with Gilead Sciences and Sanofi.
Symbol: NRIX
Recent Price: $18.64
Industry: Biotechnology
CEO: Dr. Arthur T. Sands M.D., Ph.D.
Sector: Healthcare
Employees: 284
Address: 1700 Owens Street, San Francisco, CA 94158
Phone: 415 660 5320
Last updated: 2024-12-31
TransCode Therapeutics, Inc.
TTX-MC138
Trans Code Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing drugs and diagnostics for treating metastatic disease. Their lead product, TTX-MC138, is aimed at metastatic cancer treatment, along with a range of other therapeutic platforms targeting cancer through innovative RNA- and CRISPR-based technologies.
Symbol: RNAZ
Recent Price: $3.76
Industry: Biotechnology
CEO: Mr. Thomas A. Fitzgerald M.B.A.
Sector: Healthcare
Employees: 10
Address: 6 Liberty Square, Boston, MA 02109
Phone: 857-837-3099
Last updated: 2024-12-31
TRACON Pharmaceuticals, Inc.
therapeutics for cancer
TRACON Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing cancer therapeutics, including clinical stage products like envafolimab, YH001, TRC102, and TJ004309, with collaboration agreements with various biopharmaceutical companies.
Symbol: TCON
Recent Price: $0.03
Industry: Biotechnology
CEO: Mr. Craig R. Jalbert CIRA
Sector: Healthcare
Employees: 17
Address: 4350 La Jolla Village Drive, San Diego, CA 92122
Phone: 858 550 0780
Last updated: 2024-12-31
TScan Therapeutics, Inc.
T cell receptor-engineered T cell therapies
TScan Therapeutics, Inc. is a preclinical-stage biopharmaceutical company that develops T cell receptor-engineered T cell therapies for cancer treatment. It is working on therapies for hematologic malignancies and solid tumors, as well as vaccines for infectious diseases like SARS-CoV-2.
About | About | Management | Directors | About | About | Contact | Careers | Careers | Careers | About | About
Symbol: TCRX
Recent Price: $3.00
Industry: Biotechnology
CEO: Dr. Gavin MacBeath Ph.D.
Sector: Healthcare
Employees: 175
Address: 830 Winter Street, Waltham, MA 02451
Phone: 857 399 9500
Leadership
- Stephen Biggar, M.D., Ph.D., Partner at Baker Bros. Advisors LP
- Katina Dorton, J.D., M.B.A., CFO of Nodthera
- Gabriela Gruia, M.D., Chief Development Officer at Ichnos Sciences
- Barbara Klencke, M.D., Former Chief Medical Officer and Chief Development Officer of Sierra Oncology Inc.
- Gavin MacBeath, Ph.D., CEO of TSCAN
- Garry Nicholson, Former President of Pfizer Oncology
- R. Keith Woods, Former Chief Operating Officer of argenx
Last updated: 2024-12-31
Tempest Therapeutics, Inc.
TPST-1495, TPST-1120, TREX-1
Tempest Therapeutics Inc. is a clinical-stage oncology company developing small molecule therapeutics to treat cancer, with key programs in TPST-1495 and TPST-1120, and research in TREX-1 enzyme modulation.
Symbol: TPST
Recent Price: $0.84
Industry: Biotechnology
CEO: Mr. Stephen R. Brady J.D., LLM
Sector: Healthcare
Employees: 17
Address: 7000 Shoreline Court, South San Francisco, CA 94080
Phone: 415 798 8589
Last updated: 2024-12-31
Turnstone Biologics Corp.
TIDAL-01
Turnstone Biologics Corp. is a clinical stage biotechnology company focused on developing medicines for treating and curing patients with solid tumors. Its lead product, TIDAL-01, is in Phase 1 clinical trials for various cancers.
About | About | About | About | About | About | About | About | About | About | About | About
Symbol: TSBX
Recent Price: $0.50
Industry: Biotechnology
CEO: Dr. Sammy J. Farah M.B.A., Ph.D.
Sector: Healthcare
Employees: 82
Address: 9310 Athena Circle, LA Jolla, CA 92037
Phone: 347-897-5988
Last updated: 2024-12-31
2seventy bio, Inc.
idecabtagene vicleucel
2seventy bio, Inc. is a cell and gene therapy company focusing on cancer treatment research, development, and commercialization, with products including idecabtagene vicleucel and collaborations with Bristol-Myers Squibb.
Symbol: TSVT
Recent Price: $2.89
Industry: Biotechnology
CEO: Mr. William D. Baird III, M.B.A.
Sector: Healthcare
Employees: 274
Address: 60 Binney Street, Cambridge, MA 02142
Phone: 339 499 9300
Last updated: 2024-12-31
IN8bio, Inc.
INB-200, INB-100, INB-400, INB-300
IN8bio, Inc. is a clinical-stage biotechnology company focused on gamma-delta T cell therapies for cancer treatment, with lead products in clinical trials and preclinical development.
Symbol: INAB
Recent Price: $0.27
Industry: Biotechnology
CEO: Mr. Tai-Wei Ho
Sector: Healthcare
Employees: 39
Address: 350 5th Avenue, New York, NY 10118
Phone: 646 600 6438
Last updated: 2024-12-31
Terns Pharmaceuticals, Inc.
TERN-101, TERN-201, TERN-501, TERN-601
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for non-alcoholic steatohepatitis (NASH) and obesity, incorporating products like TERN-101, TERN-201, TERN-501, and TERN-601.
About | Contact | Careers | Careers | Careers | About | About | Careers | Culture | About | Leadership | About
Symbol: TERN
Recent Price: $7.15
Industry: Biotechnology
CEO: Ms. Amy L. Burroughs M.B.A.
Sector: Healthcare
Employees: 66
Address: 1065 East Hillsdale Boulevard, Foster City, CA 94404
Phone: 650 525 5535
Last updated: 2024-11-08
Tango Therapeutics, Inc.
TNG908
Tango Therapeutics, Inc. is a biotechnology company focused on discovering and developing drugs for cancer treatment, with a lead program TNG908 targeting cancers with methylthioadenosine phosphorylase deletions. The company also works on therapies for BRCA1/2-mutant and STK11-mutant cancers and collaborates with Gilead Sciences, Inc.
Symbol: TNGX
Recent Price: $3.10
Industry: Biotechnology
CEO: Dr. Barbara L. Weber M.D.
Sector: Healthcare
Employees: 140
Address: 100 Binney Street, Cambridge, MA 02142
Phone: 857 320 4900
Last updated: 2024-12-31